Sequence Study of Risankizumab vs Ustekinumab in CD
David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.
EP: 1.Factors Guiding Treatment Choice in Crohn’s Disease
EP: 2.Moving Beyond Symptom Control in CD
EP: 3.Starting Biologic Treatment Early in CD
EP: 4.Treat-to-Target in CD
EP: 5.Monitoring Treatment Response in Treat-to-Target in CD
EP: 6.Engaging Patients to Achieve Treatment Goals in CD
EP: 7.Encouraging Patients for Biologic Use in Early Treatment of CD
EP: 8.Anti-TNF and Anti-Integrins for Treatment of CD
EP: 9.Role of IL-12/23 Inhibitors and IL-23 Inhibitors in CD
EP: 10.Sequence Study of Risankizumab vs Ustekinumab in CD
EP: 11.Use of Upadacitinib in Treatment of CD
EP: 12.Selecting CD Treatment in Special Scenarios
This is a video synopsis/summary of a panel discussion involving Marla Dubinsky, MD; David Rubin, MD; Miguel Regueiro, MD; Remo Panaccione, MD, FRCPC; and Sara Horst, MD, MPH.
The transcript discusses the findings of the sequence study, focusing on the comparison between two drugs, P41 (referred to as risankizumab) and P19 (referred to as IL (interleukin)-23 therapy). The study aimed to evaluate the efficacy of risankizumab in patients with Crohn's disease who had been exposed to TNF.
The results indicate that risankizumab-exposed patients were more likely to achieve clinical response, clinical remission, and endoscopic improvement compared to those on P40 (risankizumab with IL-12 and IL-23). The transcript emphasizes that the head-to-head comparison provides valuable insights, guiding clinicians in choosing the most effective therapy.
It highlights that risankizumab, along with its biosimilar, is an approved and effective option for Crohn's disease. The discussion touches upon the significance of the sequence study's second primary endpoint, endoscopic remission, and how it could be a pivotal moment in the field.
The conversation also touches on the evolution of clinical trials in Crohn's disease, emphasizing the importance of endoscopic outcomes and the progression from subjective measures to objective proof of efficacy. The participants express optimism about the potential impact of risankizumab, especially when used as a first-line therapy.
Furthermore, the transcript discusses the importance of early intervention in Crohn's disease, suggesting that initiating treatment early is more likely to result in a positive response and prevent further damage. The participants encourage setting higher expectations for patients and discuss the advantages of using risankizumab in biologic treatment-naive patients.
In conclusion, the discussion underscores the positive findings from the sequence study, positioning risankizumab as a promising option for Crohn's disease, particularly in terms of achieving endoscopic remission and improving patient outcomes. The participants stress the need for effective communication with patients about treatment options and the potential long-term benefits of early intervention.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
